Anbio Biotechnology Debt
| NNNN Stock | 32.39 1.11 3.31% |
As of the 30th of December 2025, Net Debt is likely to drop to about (12.3 M). In addition to that, Net Debt To EBITDA is likely to drop to -4.81 With a high degree of financial leverage come high-interest payments, which usually reduce Anbio Biotechnology's Earnings Per Share (EPS).
Debt Ratio | First Reported 2010-12-31 | Previous Quarter 0.0 | Current Value 0.0 | Quarterly Volatility 0.0 |
Anbio Biotechnology Bond Ratings
Anbio Biotechnology Class financial ratings play a critical role in determining how much Anbio Biotechnology have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for Anbio Biotechnology's borrowing costs.| Piotroski F Score | 5 | Healthy | View |
| Beneish M Score | (2.96) | Unlikely Manipulator | View |
Anbio Biotechnology Total Assets Over Time
Anbio Biotechnology Assets Financed by Debt
Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Anbio Biotechnology's operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Anbio Biotechnology, which in turn will lower the firm's financial flexibility.Anbio Biotechnology Corporate Bonds Issued
Anbio Net Debt
Understaning Anbio Biotechnology Use of Financial Leverage
Leverage ratios show Anbio Biotechnology's total debt position, including all outstanding obligations. In simple terms, high financial leverage means that the cost of production, along with the day-to-day running of the business, is high. Conversely, lower financial leverage implies lower fixed cost investment in the business, which is generally considered a good sign by investors. The degree of Anbio Biotechnology's financial leverage can be measured in several ways, including ratios such as the debt-to-equity ratio (total debt / total equity), or the debt ratio (total debt / total assets).
| Last Reported | Projected for Next Year | ||
| Net Debt | -11.8 M | -12.3 M | |
| Net Debt To EBITDA | (4.58) | (4.81) |
Pair Trading with Anbio Biotechnology
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Anbio Biotechnology position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Anbio Biotechnology will appreciate offsetting losses from the drop in the long position's value.Moving against Anbio Stock
| 0.57 | DTIL | Precision BioSciences | PairCorr |
| 0.42 | VCEL | Vericel Corp Ord | PairCorr |
| 0.36 | VKTX | Viking Therapeutics | PairCorr |
| 0.34 | PYC | Physiomics Plc | PairCorr |
| 0.31 | VANI | Vivani Medical | PairCorr |
The ability to find closely correlated positions to Anbio Biotechnology could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Anbio Biotechnology when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Anbio Biotechnology - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Anbio Biotechnology Class to buy it.
The correlation of Anbio Biotechnology is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Anbio Biotechnology moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Anbio Biotechnology Class moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Anbio Biotechnology can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of Anbio Biotechnology Fundamentals Over Time. You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Anbio Biotechnology. If investors know Anbio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Anbio Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 0.05 | Revenue Per Share | Quarterly Revenue Growth (0.36) | Return On Assets | Return On Equity |
The market value of Anbio Biotechnology Class is measured differently than its book value, which is the value of Anbio that is recorded on the company's balance sheet. Investors also form their own opinion of Anbio Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is Anbio Biotechnology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Anbio Biotechnology's market value can be influenced by many factors that don't directly affect Anbio Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Anbio Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Anbio Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Anbio Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
What is Financial Leverage?
Financial leverage is the use of borrowed money (debt) to finance the purchase of assets with the expectation that the income or capital gain from the new asset will exceed the cost of borrowing. In most cases, the debt provider will limit how much risk it is ready to take and indicate a limit on the extent of the leverage it will allow. In the case of asset-backed lending, the financial provider uses the assets as collateral until the borrower repays the loan. In the case of a cash flow loan, the general creditworthiness of the company is used to back the loan. The concept of leverage is common in the business world. It is mostly used to boost the returns on equity capital of a company, especially when the business is unable to increase its operating efficiency and returns on total investment. Because earnings on borrowing are higher than the interest payable on debt, the company's total earnings will increase, ultimately boosting stockholders' profits.Leverage and Capital Costs
The debt to equity ratio plays a role in the working average cost of capital (WACC). The overall interest on debt represents the break-even point that must be obtained to profitability in a given venture. Thus, WACC is essentially the average interest an organization owes on the capital it has borrowed for leverage. Let's say equity represents 60% of borrowed capital, and debt is 40%. This results in a financial leverage calculation of 40/60, or 0.6667. The organization owes 10% on all equity and 5% on all debt. That means that the weighted average cost of capital is (.4)(5) + (.6)(10) - or 8%. For every $10,000 borrowed, this organization will owe $800 in interest. Profit must be higher than 8% on the project to offset the cost of interest and justify this leverage.Benefits of Financial Leverage
Leverage provides the following benefits for companies:- Leverage is an essential tool a company's management can use to make the best financing and investment decisions.
- It provides a variety of financing sources by which the firm can achieve its target earnings.
- Leverage is also an essential technique in investing as it helps companies set a threshold for the expansion of business operations. For example, it can be used to recommend restrictions on business expansion once the projected return on additional investment is lower than the cost of debt.